Sam Brusco, Associate Editor01.13.23
HVR Cardio, a clinical-stage firm developing structural heart products for transcatheter mitral valve repair, has closed on a €10.7 million ($11.1 million) Series B round of financing. It was led by Innovester Life Science Fund and Test, which are both based in Finland.
HVR Cardio also revealed a new leadership team. Tom Fleming joined the company in May 2022; he has 21 years’ experience at Boston Scientific culminating in the role of VP and GM for its structural heart valve business. Before this, he was CEO of 4Tech Inc. Tim Girton joined as chief technology officer in July 2022 with a 23+ year background at Boston Scientific, with his most recent roles as VP of R&D for interventional cardiology.
HVR Cardio is developing the CathHELIX annuloplasty system to treat mitral regurgitation (MR). The firm’s new Helix ring tech aims to be a simple, safe, and secure transcatheter annuloplasty procedure allowing for reduction in MR without tethering the native leaflets.
"The potential of this innovative technology is why I joined the team," Fleming told the press. "This funding enables our next step into Human Clinical trials and allows us to expand our team."
"MR is a common valvular heart disease impacting millions of people and leaving a significant need for better treatment options. We are truly excited about the elegant and minimally invasive CathHELIX technology that will offer new hope for patients," added Pekka Simula, Partner of Innovestor Life Science.
CathHELIX is investigational and not approved or cleared for any geography.
HVR Cardio also revealed a new leadership team. Tom Fleming joined the company in May 2022; he has 21 years’ experience at Boston Scientific culminating in the role of VP and GM for its structural heart valve business. Before this, he was CEO of 4Tech Inc. Tim Girton joined as chief technology officer in July 2022 with a 23+ year background at Boston Scientific, with his most recent roles as VP of R&D for interventional cardiology.
HVR Cardio is developing the CathHELIX annuloplasty system to treat mitral regurgitation (MR). The firm’s new Helix ring tech aims to be a simple, safe, and secure transcatheter annuloplasty procedure allowing for reduction in MR without tethering the native leaflets.
"The potential of this innovative technology is why I joined the team," Fleming told the press. "This funding enables our next step into Human Clinical trials and allows us to expand our team."
"MR is a common valvular heart disease impacting millions of people and leaving a significant need for better treatment options. We are truly excited about the elegant and minimally invasive CathHELIX technology that will offer new hope for patients," added Pekka Simula, Partner of Innovestor Life Science.
CathHELIX is investigational and not approved or cleared for any geography.